Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2026. The report serves as a transaction notification regarding a purchase of American Depositary Shares (ADS) by a Person Discharging Managerial Responsibilities (PDMR) under the company's pension plan.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ADS under GSK pension plan |
| Instrument | American Depositary Shares (ISIN: US37733W2044) |
| Volume | 11.163 ADS |
| Price | CAD 82.8205 per ADS |
| Transaction Date | February 13, 2026 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing does not contain comparative financial data or material changes to the company's operations versus prior periods. The only reported change is the increase in share ownership by the specified executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It includes a standard corporate description stating GSK is a global biopharma company focused on uniting science, technology, and talent.
Investor Verification Checklist
- Verify the identity of the PDMR: Diana Conrad, Chief People Officer.
- Confirm the transaction was an acquisition under the GSK pension plan, not a discretionary trade.
- Note the transaction currency is Canadian Dollars (CAD), not USD.
- Check the volume of 11.163 ADS, which represents a very small position relative to total outstanding shares.
- Confirm the transaction date of February 13, 2026, against the filing date of February 25, 2026.